THINK Disappoints in High-Risk MDS and AML Patients

(MedPage Today) -- NKG2D is an activating receptor capable of binding eight ligands overexpressed in AML/MDS. The THINK study evaluated CYAD-01 with no preconditioning, and the DEPLETHINK study trialed CYAD-01 with cyclophosphamide and fludarabine...